Navigation Links
ABAXIS Announces Launch of Two New Products at the NAVC
Date:1/16/2009

Company will launch the VetScan(R) VSpro Coagulation Analyzer and VetScan Canine Heartworm Rapid Test at the largest Veterinary Conference in North America

UNION CITY, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis instruments for both the medical and veterinary markets, announced today that it will launch the VetScan VSpro Coagulation Analyzer and VetScan Canine Heartworm Rapid Test at the North American Veterinary Conference in Orlando, Florida on Sunday, January 18th. This conference draws veterinarians and veterinary technicians from around the world, and it is expected that over 7,000 veterinary professionals will be in attendance.

The VetScan Canine Heartworm rapid test is expected to be the first in a series of rapid, lateral flow tests to be released by Abaxis. The test will provide a simple, accurate, and highly cost-effective option for veterinarians to use for their heartworm testing. The US heartworm market is believed to be greater than $70 million per year.

The VetScan VSpro Coagulation Analyzer will allow veterinarians to evaluate PT and aPTT results using a state-of-the-art, in-house / point of care technology. The analyzer will be used in combination with a sophisticated, micro-fluidic technology based cartridge that contains all the reagents necessary to perform PT and aPTT testing. The VetScan VSpro can be combined with the Abaxis VetScan Chemistry and VetScan Hematology instruments to provide veterinarians with a complete clinical picture for critically ill patients, pre-surgical work-ups and for routine wellness exams.

Martin Mulroy, Vice President Sales and Marketing commented "We are very excited to add these two new products to the Abaxis product portfolio. These products, used alone or in conjunction with the VetScan Chemistry and VetScan Hematology products, demonstrate Abaxis' commitment to serving the Veterinary and Research community with high quality, innovative, and always cost-effective products. In this challenging economic environment, the marketplace will be looking to decrease costs and add efficiencies, one of the core strengths of the Abaxis product line." Michael Solomon, Director of Business Development added, "The addition of our first rapid diagnostic product along with an innovative micro-fluidic technology for coagulation testing further strengthens the current Abaxis product portfolio while creating the opportunity for future products and accelerated growth."

About Abaxis, Inc.

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. The veterinary business also provides to the veterinarian and research market a line of hematology instruments for point of care complete blood counts (CBC).

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, risks involved in carrying of inventory, risks from unexpected problems or delays in the Company's manufacturing facility, risks associated with the ability to attract and retain competent sales personnel, general market conditions, competition, risks and uncertainties related to its ability to raise capital in order to fund its operations and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Clint Severson               Lytham Partners, LLC
    Chief Executive Officer      Joe Dorame, Robert Blum and Joe Diaz
    Abaxis, Inc.                 602-889-9700
    510-675-6500


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd.
2. Abaxis, Inc. to Present at Sidoti & Companys Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum
3. Abaxis, Inc. to Present at Needham & Companys Eleventh Annual Growth Stock Conference
4. Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status
5. Abaxis, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Abaxis to Report Second Quarter Fiscal 2009 Financial Results Monday, October 27, 2008
7. Abaxis, Inc. to Present at CL Kings Sixth Annual Best Ideas Conference
8. Abaxis, Inc. CEO to Present at the Eighth Annual Forbes Global CEO Conference in Singapore
9. Abaxis to Report First Quarter Fiscal 2009 Financial Results Thursday, July 24, 2008
10. Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference
11. Abaxis, Inc. to Present at the Sidoti & Company Twelfth Annual New York Emerging Growth Institutional Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... Americans facing life-altering and fatal diseases in opposition to the President’s Fiscal ... would eviscerate care, services, and hope for the most vulnerable among us. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, ...                  , How will the new EU MDR language change the way ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... News Advisory/Interview ... Choice has helped score a major victory in Europe for public health and the ... , Based on rigorous scientific research and the overwhelming support of European citizens, ...
(Date:3/23/2017)... ... ... “My Journey Through Heaven”: the true-life account of a man who faced ... promise of Heaven for His people. “My Journey Through Heaven” is the creation of ... children and six grandchildren living and doing for God as best they can. , ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “The Trainer”: ... creation of published author, Scotty, a fiction writer with an active imagination and an ... Scotty’s new book follows the tale of Wild Bill Hart, who sat looking at ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 23, 2017 ReportsnReports.com adds Global ... research report. The global vagus nerve stimulation market analyst ... focus toward minimally invasive VNS procedures. Few years ago, ... developed countries having high standards of healthcare infrastructure. ... ...
(Date:3/22/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 10.9% over the next decade to reach approximately $38.27 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... 22, 2017  "Global Biosimilar Insulin Market ... gives comprehensive insight on clinical and non-clinical ... insulin market. This report analyzes various aspects ... of insulin in diabetes, engineering of synthetic ... with market overview, biosimilar insulin clinical pipeline ...
Breaking Medicine Technology: